Immunotherapy

LAWRENCEVILLE, N.J. — September 22, 2026 IMUNON announced that the Independent Data Monitoring Committee (IDMC) overseeing its Phase 2...

OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...

NANTES, France — September 23, 2026 OSE Immunotherapeutics announced that topline results from the Combi-TED Phase 2 trial of...

Uppsala, Sweden, September 22, 2026 Beactica Therapeutics AB has announced the initiation of IND-enabling studies for BEA-17, its wholly...

Waltham, Massachusetts, U.S., September 21, 2026 Q32 Bio Inc., a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory...

Raritan, New Jersey, U.S., September 18, 2026 Johnson & Johnson has announced that the European Medicines Agency’s Committee for...

Tokyo, Japan, September 17, 2026 Astellas Pharma Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products...

AGOURA HILLS, Calif. — September 15, 2026 A2 Biotherapeutics announced encouraging early safety and efficacy findings from the ongoing...

SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Genentech announced that the Phase III CELESTIMO study of Lunsumio® (mosunetuzumab-axgb)...

San Diego, California, U.S., September 14, 2026 AbelZeta Therapeutics has announced that the U.S. Food and Drug Administration (FDA)...